The independent and combined risk of diabetes and non-endstage renal impairment in non-ST-segment elevation acute coronary syndromes.

[1]  J. Núñez,et al.  Intravenous N-acetylcysteine for preventing contrast-induced nephropathy: a randomised trial. , 2007, International journal of cardiology.

[2]  F. Veglia,et al.  N-Acetylcysteine and Contrast-Induced Nephropathy in Primary Angioplasty , 2006 .

[3]  P. Parfrey,et al.  Preventing Nephropathy Induced by Contrast Medium , 2006 .

[4]  J. Dubois-Randé,et al.  Prognostic significance of renal insufficiency in patients presenting with acute coronary syndrome (the Prospective Multicenter SYCOMORE study). , 2004, The American journal of cardiology.

[5]  B. Brenner,et al.  From secondary to primary prevention of progressive renal disease: the case for screening for albuminuria. , 2004, Kidney international.

[6]  E. Antman,et al.  Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome; observations in 13,307 patients in five TIMI trials. , 2004, European heart journal.

[7]  R. Gupta,et al.  The renal patient with coronary artery disease: current concepts and dilemmas. , 2004, Journal of the American College of Cardiology.

[8]  Robert M Califf,et al.  Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. , 2004, The New England journal of medicine.

[9]  Neil J Stone,et al.  Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.

[10]  E. Topol,et al.  Double jeopardy of renal insufficiency and anemia in patients undergoing percutaneous coronary interventions. , 2004, The American journal of cardiology.

[11]  J. Rumsfeld,et al.  Renal insufficiency and mortality from acute coronary syndromes. , 2004, American heart journal.

[12]  N. Lamblin,et al.  Impact of diabetes mellitus on long-term survival in patients with congestive heart failure. , 2004, European heart journal.

[13]  J. J. Griffin,et al.  Impact of Renal Insufficiency in Patients Undergoing Primary Angioplasty for Acute Myocardial Infarction , 2003, Circulation.

[14]  E. Antman,et al.  Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. , 2003, Journal of the American College of Cardiology.

[15]  Bertram L Kasiske,et al.  Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. , 2003, Hypertension.

[16]  W. McClellan,et al.  Renal insufficiency and anemia are independent risk factors for death among patients with acute myocardial infarction. , 2003, Kidney international.

[17]  C. Herzog,et al.  Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. , 2003, JAMA.

[18]  G. Eknoyan,et al.  National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification , 2003, Annals of Internal Medicine.

[19]  J. Cooper,et al.  Renal function and risk stratification in acute coronary syndromes. , 2003, The American journal of cardiology.

[20]  E. Braunwald,et al.  Effects of renal insufficiency on early invasive management in patients with acute coronary syndromes (The TACTICS-TIMI 18 Trial). , 2002, The American journal of cardiology.

[21]  C. Camargo,et al.  Elevated serum creatinine is associated with 1-year mortality after acute myocardial infarction. , 2002, American heart journal.

[22]  M. Mcclellan,et al.  Association of Renal Insufficiency with Treatment and Outcomes after Myocardial Infarction in Elderly Patients , 2002, Annals of Internal Medicine.

[23]  R. Califf,et al.  Prognostic Implications of Abnormalities in Renal Function in Patients With Acute Coronary Syndromes , 2002, Circulation.

[24]  R. Califf,et al.  Outcomes of Patients With Chronic Renal Insufficiency in the Bypass Angioplasty Revascularization Investigation , 2002, Circulation.

[25]  Ethan M Balk,et al.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[26]  S. Yusuf,et al.  Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. , 2001, JAMA.

[27]  W. Bloembergen,et al.  Prevalence and clinical correlates of coronary artery disease among new dialysis patients in the United States: a cross-sectional study. , 2001, Journal of the American Society of Nephrology : JASN.

[28]  E. Braunwald,et al.  Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. , 2001, The New England journal of medicine.

[29]  I. Palacios,et al.  Effectiveness of and adverse events after percutaneous coronary intervention in patients with mild versus severe renal failure. , 2001, The American journal of cardiology.

[30]  E. Antman,et al.  The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. , 2000, JAMA.

[31]  A. Skene,et al.  Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. , 2000, Circulation.

[32]  A. Charlesworth,et al.  Renal function, neurohormonal activation, and survival in patients with chronic heart failure. , 2000, Circulation.

[33]  E. Antman,et al.  Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. , 1999, Circulation.

[34]  C. Wanner,et al.  Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. , 1999, Kidney international.

[35]  E. Braunwald,et al.  Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction. , 1998, Circulation.

[36]  A. Donker,et al.  Endothelial dysfunction and pathogenesis of diabetic angiopathy. , 1997, Cardiovascular research.

[37]  S. Cobbe.  Thrombolysis in myocardial infarction , 1994, BMJ.